| Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model A Kieffer, M Beuvelet, A Sardesai, R Musci, S Milev, J Roiz, JKH Lee The Journal of Infectious Diseases 226 (Supplement_2), S282-S292, 2022 | 51 | 2022 |
| A path to improved Alzheimer’s care: simulating long-term health outcomes of lecanemab in early Alzheimer’s disease from the CLARITY AD trial AA Tahami Monfared, W Ye, A Sardesai, H Folse, A Chavan, E Aruffo, ... Neurology and Therapy 12 (3), 863-881, 2023 | 14 | 2023 |
| Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany A Sardesai, A Dignass, P Quon, S Milev, JC Cappelleri, A Kisser, ... Journal of Medical Economics 24 (1), 279-290, 2021 | 9 | 2021 |
| Estimated societal value of lecanemab in patients with early Alzheimer’s disease using simulation modeling AA Tahami Monfared, W Ye, A Sardesai, H Folse, A Chavan, K Kang, ... Neurology and Therapy 12 (3), 795-814, 2023 | 5 | 2023 |
| Predicting the societal value of Lecanemab in early Alzheimer’s disease in Japan: a patient-level simulation A Igarashi, MK Azuma, Q Zhang, W Ye, A Sardesai, H Folse, A Chavan, ... Neurology and Therapy 12 (4), 1133-1157, 2023 | 4 | 2023 |
| Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults≥ 65 Years I McGovern, A Sardesai, A Taylor, H Toro-Diaz, M Haag Open Forum Infectious Diseases 10 (8), ofad429, 2023 | 2 | 2023 |
| PGI9 COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY P Quon, A Sardesai, S Milev, M DiBonaventura, JC Cappelleri, A Kisser, ... Value in Health 22, S617, 2019 | 1 | 2019 |
| Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine I McGovern, A Taylor, A Sardesai, H Toro-Diaz, M Haag Expert Review of Vaccines 23 (1), 371-379, 2024 | | 2024 |
| Modelling the Potential Clinical and Economic Impact of Universal Immunization with Nirsevimab Versus Standard of Practice for Protecting All Neonates and Infants in Their … R Gil-Prieto, JJ Pérez, G Drago, A Kieffer, J Roïz, P Kazmierska, ... Available at SSRN 4572825, 2024 | | 2024 |
| 2814. The Impact of Novel Antibiotics on Curbing Antimicrobial Resistance and Infection Spread a Dynamic Modeling Study A Ambavane, M Litkiewicz, A Sardesai, D Teloian, EN Obi, J Yang Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2425, 2023 | | 2023 |
| EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort A Kieffer, A Sardesai, R Musci, M Beuvelet, MTC de Su, JKH Lee, C Rizzo, ... Value in Health 26 (12), S135, 2023 | | 2023 |
| 2640. Estimated Additional Burden Averted from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States … I McGovern, A Taylor, A Sardesai, H Toro-Diaz, M Haag Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2252, 2023 | | 2023 |
| HTA189 A Critical Appraisal of Economic Evaluations in RSV R Hudson, M Beuvelet, R Musci, E Aruffo, A Sardesai, A Kieffer Value in Health 26 (12), S355, 2023 | | 2023 |
| Response to Fullarton et al A Kieffer, M Beuvelet, A Sardesai, R Musci, S Milev, JKH Lee The Journal of Infectious Diseases 227 (11), 1335-1336, 2023 | | 2023 |
| All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have … A Kieffer, M Beuvelet, A Sardesai, R Musci, S Milev, JKH Lee in Health 2022 (11.014), 2022 | | 2022 |
| POSC143 Comparison of Model Structures Used in NICE and ICER Cost Effectiveness Evaluations S Milev, A Sardesai, SS Raj, A Taylor, J Sala, D Zou Value in Health 25 (1), S115, 2022 | | 2022 |
| PRO110 A Framework for Developing a MODEL of Chronic Acid Sphingomyelinase Defficiency H Folse, A Ward, C Chandler, M Fournier, A Sardesai, R Pulikottil-Jacob Value in Health 23, S709, 2020 | | 2020 |
| PGI23 TREATMENT COST ANALYSIS FOR PATIENTS IN THE UNITED STATES WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE AN INADEQUATE RESPONSE OR WHO ARE INTOLERANT TO … A Sardesai, S Milev, P Quon, J Bourret, K Peeples-Lamirande, L Salese, ... Value in Health 23, S146-S147, 2020 | | 2020 |
| PND40 BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES SA Foster, S Milev, M Hoog, O Mason, A Sardesai, A Hasan, C Marrone Value in Health 22, S277, 2019 | | 2019 |
